The CYP2S1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji Burkitt lymphoma B lymphocyte line, designed for targeted disruption of the CYP2S1 gene. This polyclonal knockout model enables loss-of-function studies to dissect the role of CYP2S1 in xenobiotic metabolism, retinoid signaling, and associated cellular processes without selection of single clones, thus maintaining population diversity.
The Raji cell line is an Epstein-Barr virus (EBV)-positive B lymphocyte model originally established from a Burkitt lymphoma patient. Raji cells are widely used in immunology and cancer research due to their capacity for antibody production and their representation of EBV-driven lymphomagenesis, exhibiting constitutive activation of signaling pathways such as NF-??B and AP-1 that drive proliferation and survival.
CYP2S1 is a cytochrome P450 monooxygenase that catalyzes the oxidation of retinoic acid and arachidonic acid derivatives, including prostaglandin H2. Transcription of CYP2S1 is regulated by the aryl hydrocarbon receptor (AhR) and retinoic acid receptors (RAR/RXR), while its enzymatic activity depends on electron transfer from NADPH-cytochrome P450 reductase (POR) and cytochrome b5. CYP2S1-mediated oxidation of retinoic acid generates degradation products that attenuate retinoid signaling, and conversion of prostaglandin H2 yields metabolites that promote reactive oxygen species production and inflammatory responses. Thus, CYP2S1 functions as a node linking AhR and retinoid pathways to arachidonic acid metabolism, influencing cell proliferation and differentiation.
In the Raji B lymphocyte context, knockout of CYP2S1 disrupts the metabolic processing of endogenous and xenobiotic compounds, providing a system to examine how altered retinoid and prostaglandin metabolism affects lymphoma cell behavior. Loss of CYP2S1 may reduce the catabolism of retinoic acid, potentially enhancing retinoid-mediated antiproliferative signals, while decreasing pro-inflammatory prostaglandin metabolites and reactive oxygen species levels. These changes could sensitize Raji cells to apoptotic stimuli or alter their drug sensitivity, making this model valuable for studying the interplay between metabolic enzymes and oncogenic signaling in Burkitt lymphoma.
This polyclonal knockout model is suited for a range of experimental applications, including drug metabolism studies to evaluate CYP2S1-dependent biotransformation, retinoid signaling research using RT-qPCR and Western blotting for downstream targets, and cancer biology investigations employing proliferation, apoptosis, and drug sensitivity assays. The cells can also be used in toxicology screening for compounds affecting CYP2S1 activity, as well as in inflammatory response modeling through metabolomic profiling of prostaglandin metabolites and reactive oxygen species. For additional information or to inquire about custom models, please contact Ascent Research.
